#biotech-investment

[ follow ]
#ai-stocks-correction #capital-expenditure #portfolio-diversification #valuation-reset #mdma #clinical-trials
Venture
from24/7 Wall St.
6 days ago

Forget AI. This Biotech Stock's Taking Off Right Now

AI stocks face correction risk due to rising capital expenditures without proportional profits, making biotech an undervalued alternative for AI-driven growth exposure.
fromsfist.com
5 months ago

Sam Altman-Backed SF Company Making Legal Ecstasy' Wins Approval to Conduct Clinical Trials

An SF-based biotech company is working on a safer, reformulated version of MDMA, better known as molly' or ecstasy,' and we're not tripping when we say they just won FDA approval to begin Phase 1 clinical trials. We have occasionally covered Bay Area medical research into MDMA, the street drug known as ecstasy or molly, and perhaps a little too enthusiastically at that.
Medicine
[ Load more ]